title: Enhancement of anti-inflammatory activity of PEP-1-FK506 binding protein by silk fibroin peptide.
abstract: Silk fibroin (SF) peptide has been traditionally used as a treatment for flatulence, spasms, and phlegm. In this study, we examined whether SF peptide enhanced the antiinflammatory effect of PEP-1-FK506 binding protein (PEP-1-FK506BP) through comparing the anti-inflammatory activities of SF peptide and/or PEP-1-FK506BP. In the presence or absence of SF peptide, transduction levels of PEP-1-FK506BP into HaCaT cells and mice skin and anti-inflammatory activities of PEP-1-FK506BP were identified by Western blot and histological analyses. SF peptide alone effectively reduced both mice ear edema and the elevated levels of cyclooxygenase-2, interleukin-6 and -1beta, and tumor necrosis factor-alpha, showing similar anti-inflammatory effect to that of PEP-1-FK506BP. Furthermore, co-treatment with SF peptide and PEP-1- FK506BP exhibited more enhanced anti-inflammatory effects than the samples treated with SF peptides or PEP- 1-FK506BP alone, suggesting the possibility that SF peptide and PEP-1-FK506BP might interact with each other. Moreover, the transduction data demonstrated that SF peptide did not affect the transduction of PEP-1- FK506BP into HaCaT cells and mice skin, indicating that the improvement of anti-inflammatory effect of PEP-1- FK506BP was not caused by enhanced transduction of PEP-1-FK506BP. Thus, these results suggest the possibility that co-treatment with SF peptide and PEP-1-FK506BP may be exploited as a useful therapy for various inflammationrelated diseases.
authors.affiliation: Department of Biomedical Science and Research Institute of Bioscience and Biotechnology, Hallym University, Chunchon 200-702, Korea.
authors.forename: Dae Won
authors.initials: DW
authors.lastname: Kim
authors.forename: Hyun Sook
authors.initials: HS
authors.lastname: Hwang
authors.forename: Duk-Soo
authors.initials: DS
authors.lastname: Kim
authors.forename: Seung Hoon
authors.initials: SH
authors.lastname: Sheen
authors.forename: Dong Hwa
authors.initials: DH
authors.lastname: Heo
authors.forename: Gyojun
authors.initials: G
authors.lastname: Hwang
authors.forename: Suk Hyung
authors.initials: SH
authors.lastname: Kang
authors.forename: Haeyong
authors.initials: H
authors.lastname: Kweon
authors.forename: You-Young
authors.initials: YY
authors.lastname: Jo
authors.forename: Seok Woo
authors.initials: SW
authors.lastname: Kang
authors.forename: Kwang-Gill
authors.initials: KG
authors.lastname: Lee
authors.forename: Jinseu
authors.initials: J
authors.lastname: Park
authors.forename: Won Sik
authors.initials: WS
authors.lastname: Eum
authors.forename: Yong-Jun
authors.initials: YJ
authors.lastname: Cho
authors.forename: Soo Young
authors.initials: SY
authors.lastname: Choi
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000276:immunology; D012831:Bombyx / Q000737:chemistry*; D002460:Cell Line; D004357:Drug Synergism; D004487:Edema / Q000188:drug therapy* / Q000276:immunology; D005349:Fibroins / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010455:Peptides / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology; D022061:Tacrolimus Binding Protein 1A / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D010455:Peptides; D005349:Fibroins; D022061:Tacrolimus Binding Protein 1A